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Abstract 
Background: Only recently, the scientific community gained insights on the importance of the intestinal resident 
flora for the host’s health and disease. Gut microbiota in fact plays a crucial role in modulating innate and acquired 
immune responses and thus interferes with the fragile balance inflammation versus tolerance.
Main body: Correlations between gut bacteria composition and the severity of inflammation have been studied in 
inflammatory bowel diseases. More recently similar alterations in the gut microbiota have been reported in patients 
with spondyloarthritis, whereas in rheumatoid arthritis an accumulating body of evidence evokes a pathogenic role 
for the altered oral microbiota in disease development and course. In the context of dysbiosis it is also important to 
remember that different environmental factors like stress, smoke and dietary components can induce strong bacterial 
changes and consequent exposure of the intestinal epithelium to a variety of different metabolites, many of which 
have an unknown function. In this perspective, and in complex disorders like autoimmune diseases, not only the 
genetic makeup, sex and immunologic context of the individual but also the structure of his microbial community 
should be taken into account.
Conclusions: Here we provide a review of the role of the microbiota in the onset, severity and progression of chronic 
inflammatory arthritis as well as its impact on the therapeutic management of these patients. Furthermore we point-
out the complex interwoven link between gut-joint-brain and immune system by reviewing the most recent data on 
the literature on the importance of environmental factors such as diet, smoke and stress.
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Background
Recent advances in sequencing technologies have 
allowed the deep characterization of the human micro-
biota, thus greatly improving our knowledge on the role 
of the microbiome in human health and disease. Human 
microbiome project consortium studies [1] demonstrated 
that healthy individuals have not only a high degree of 
bacterial diversity, dependent on their habitat (intes-
tine, oral cavity, skin or vagina), but that there is also a 
remarkable inter-individual variability at the level of 
species. In spite of the large amount of different species 
found at different sites, at the level of microbial com-
munity there is evidence for a certain constancy that 
preserves both the function and the bacterial gene pro-
filing associated to specific tissue sites. For example the 
anaerobic firmicutes/bacteroidetes spp. dominate the 
intestine whereas actinobacteria and proteobacteria spp. 
are highly abundant in the skin. Given the strong vari-
ability and abundance of microbes living in close relation 
with us, it becomes a difficult task to define what should 
be considered the “normal” microbiome. Moreover, the 
same microbe may behave as commensal or as pathogen 
depending on the dietary components, nutritional milieu, 
co-infection or genetic background of its host. Albeit, it 
is still generally accepted that commensal bacteria con-
tribute to immune homeostasis, whereas immune reac-
tion against intestinal flora is accepted as a pathological 
sign. This distinction, however, is not absolute, because 
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it is possible to find in serum of healthy subjects antibod-
ies specific to commensals as well as circulating T cells 
able to react against non-pathogenic bacteria [2, 3]. Gut 
colonization, at birth, is indispensable to trigger and 
endure maturation of the mucosal immune system. At 
this phase, in which the immune structures are not yet 
fully developed, microbiota plays a crucial role in set-
ting-up innate and acquired immune responses and thus 
interferes with the fragile balance among inflammation, 
infection and tolerance that may be “imprinted” for life. 
It is known that germ-free mice have hypoplastic Payer’s 
patches (PP), lack isolated lymphoid follicles (ILF) in the 
intestine and have low levels of IgM natural antibodies 
in the serum and that this phenotype can be reverted by 
gut colonization [4]. Undoubtedly, colonization of the 
distal small intestine by segmented filamentous bacteria 
(SFB) is crucial for the development of resident lamina 
propria dendritic cells to secrete IL-6 and IL-22 trigger-
ing the loop of Th17-T regulatory (Treg) cell [5] genera-
tion in the new-born gut. The discovery of a link between 
defined members of the microbiota and the induction of 
Treg cells generated a huge interest. However, very recent 
studies demonstrate that the homeostasis of the colonic 
Treg compartment relies more on the synergistic effect 
of different bacterial strains than on a single individual 
species of that strain. This observation strongly suggests 
the importance of the bacterial community in creat-
ing a microenvironment able to sustain the generation 
and maintenance of the anti-inflammatory milieu [6, 7]. 
Another player, particularly important in the develop-
ment of arthritis that depends upon SFB colonization, 
is the follicular T helper cell (Tfh). Tfh cells are a T cell 
subset specialized in providing T cell help to B cells in 
the context of germinal center (GC) formation. By induc-
ing somatic hypermutation and class switching Tfh cells 
promote the generation of high affinity antigen specific 
memory B cells as well as antibody producing cells [8, 
9]. Several studies have recently shown, in a K/BxN RA 
mouse model [10], that SFB interferes with Tfh differen-
tiation in Payer’s Patches and supports antigen specific 
Tfh dissemination at systemic sites resulting at increased 
autoantibody production [11, 12].
As mentioned before not only bacteria but also bacte-
rial-derived products can directly or indirectly control 
the function of epithelial and inflammatory cells and 
thus being key factors in initiating/maintaining disease. 
For instance, recognition of the metabolite short-chain 
fatty acids (SCFAs) by innate immune cells is critical 
for the regulation of inflammation in response not only 
to intestinal injury, but also in arthritis and allergy [13]. 
Commensals can also tune the inflammatory poten-
tial of monocytes by promoting the production of the 
lipid mediator PGE2 that, in turn, reduces activation 
of tissue-damaging neutrophils [14]. In addition to the 
intestinal microbiota with its regulatory elements, stud-
ies describing the microorganism composition of the 
oral cavity have also been undertaken and will soon give 
new insights on human health and disease. The oral 
mucosa contains several “ecological” niches that are able 
to harbor a large variety of bacteria, viruses and fungi. 
Although the oral microbiome may be influenced by diet, 
oral hygiene and smoke, a recent study showed that oral 
microbiome of rheumatoid arthritis (RA) individuals 
correlates with patient clinical features and differs from 
microbiome of healthy controls [15]. In conclusion, sig-
nificant efforts have been recently undertaken to better 
understand our microbiome in terms of composition and 
metabolic pathways aiming at using microbes or micro-
bial products for targeted therapy in various immunolog-
ical dysfunctions, including autoimmunity.
Microbioma and host genetic background
Host genetic background, and in particular major his-
tocompatibility complex (MHC) genes, plays a pivotal 
role in the microbial composition of the gut [16]. In this 
context, to the previously genome-wide studies in which 
association between HLA genes and susceptibility to 
autoimmunity has been demonstrated, the microbiome 
as potential environmental factor causing disease should 
now be inserted. It is known that certain HLA class-II 
alleles, such as the sequence 60-74 in the third hyper-
variable region 3 of DRB1*0401 gene, are associated 
with increased susceptibility to RA, not only caused by 
abnormal CD4 T cell activation, but also due to the gen-
eration of autoantibodies. In this case, infectious agents 
trigger the production of antibodies against self-antigens 
through a mechanism called molecular mimicry or cross-
reactivity [17]. Another example is given by the HLA 
B27, HLA with strong genetic risk factor for the patho-
genesis of spondyloarthritis (SpA), that has an amino 
acid sequence shared with a nitrogenase from Klebsiella 
and other proteins present in Gram-negative bacteria. 
In this case, antigen mimicry induces cross-reactivity 
between microbial epitopes and self-proteins resulting 
in autoreactive immune responses. The contribution of 
antigen mimicry in promoting autoimmune disease has 
been confirmed in rodents expressing human HLA B27 
molecules that are preserved from developing peripheral 
arthritis, similar to SpA disease, when raised in a germ-
free environment [18, 19]. Although pathogenic bacteria 
are clearly involved in promoting autoimmune diseases 
also nonpathogenic commensal bacteria may play a role 
through the chronic activation of the innate and acquired 
immune responses [20]. Worth to mention that often in 
rheumatic diseases, patients may present leakage of the 
mucosal barrier or altered immune functions strongly 
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conditioning the persistence of antigenic stimulation 
even at articular sites [21]. In the context of altered 
immune functions, Toll like receptors (TLR) by modulat-
ing the binding to bacterial products, interfere with Th17 
generation and inflammation and thus may contribute to 
the persistence of RA disease [22]. Notwithstanding TLR 
polymorphisms were shown not to be directly involved 
in RA pathogenesis [23, 24], its role, not only in regulat-
ing innate immune responses, but also in the epithelial 
cell homeostasis at mucosal sites, may upon environ-
mental exposure become a pathogenic factor. Another 
important class of receptors linked to bacterial sensing 
are G-couple protein receptors family (GPR). Several 
members of this family are orphan receptors binding 
several ligands including bacterial products and dietary 
metabolites derived from gut microbiota. The receptor 
with the strongest link with bacterial sensing is the cas-
pase recruitment domain-containing 9 (CARD9). This 
receptor is strongly associated with disease in Crohn’s 
patients, and although CARD9 polymorphisms result-
ing in reduced CARD9 expression have been identified in 
AS, further studies are needed to sustain the association 
between CARD9 and AS disease [25, 26].
Microbiota and spondyloarthritis
SpA are chronic progressively disabling inflammatory 
diseases with a reported prevalence of 2.4/1000 and with 
a number of estimate patients of 1.5 × 106 only in Europe 
[27]. The SpA group includes ankylosing spondylitis (AS), 
psoriatic arthritis (PsA), reactive arthritis, SpA associ-
ated to inflammatory bowel disease (IBD) (also known 
as enteropathic arthritis), acute anterior uveitis and the 
most recently acquainted axial non radiographic SpA. 
Since their pleomorphic phenotype SpA early diagnosis 
and management is often a challenge for the clinician. In 
fact, SpA patients may come to the healthcare units with 
an axial involvement (i.e. sacroiliitis) and/or peripheral 
arthritis frequently associated to extra-articular mani-
festations affecting skin, eyes, and intestine. In particular 
SpA shares various clinical, genetic and immunological 
features with IBD and, although enteropathic SpA rep-
resents the clinical evidence of association between the 
two, subclinical intestinal abnormalities can be found 
up to 50 % of SpA patients [28]. Translocation of intes-
tinal microbes, caused by the increased permeability of 
the intestinal epithelial cell layer, or increased exposure 
to microbial products are two possible links connecting 
gut dysbiosis and joint pathology [29]. In recent years 
different authors have reported abnormalities in the gut 
microbiota in patients with IBD, suggesting that these 
diseases can result from altered interactions between 
gut microbes and the mucosal immune system [30–32]. 
Although, gut microorganism composition plays an 
important role in chronic inflammatory disorders, no 
specific bacterial strain has been yet identified as instru-
mental cause of the disease. Since SpA is frequently asso-
ciated to IBD, it is coherent to hypothesize a potential 
role for the gut microbiota and consequently for dysbiosis 
also in SpA pathogenesis. Indeed, the first experimental 
evidence for this link aroused from the animal model of 
human AS [33]. The ankylosing enthesopathy (ANKENT) 
mouse which is spared from developing joint ankylosis 
in germfree environment develops a less severe form of 
the disease in pathogen-free conditions [34]. Another 
study, in germfree HLAB27/human β2 microglobulin 
transgenic rats using bacterial transfers, revealed that 
only the gut colonization with bacteria isolated from the 
intestinal flora of Crohn’s disease patients was able to 
induce bowel and joint inflammatory disease [35]. More 
recently, Rosenbaum et  al. [19] using high throughput 
16S sequencing techniques studied the microbial com-
position present in the cecum of these transgenic rats 
and found a significant expansion of Prevotella and B. 
vulgatus spp. In contrast to IBD there are few data on 
the gut microbiota composition and function in SpA 
patients. Stebbings et al. are the only group that reported 
two comparative studies on the microbiota isolated from 
fecal samples of AS patients and healthy controls. In the 
first study, they found a higher proportion of sulphate-
reducing bacteria in the fecal samples from AS patients 
with no significant difference in the microbiota compo-
sition using denaturing gradient gel electrophoresis [36]. 
In the second study, using an indirect in vitro experimen-
tal approach, they observed that IL-10 production by 
peripheral blood mononuclear cells (PBMC) measured 
in the supernatants of the cell cultured with autologous 
Bacteroidetes were lower in the AS group compared with 
controls suggesting that patients have a reduced ability 
to generate tolerogenic environment in their gut [37]. 
Stool and blood specimens collected from children with 
enthesitis-related arthritis showed less Faecalibacterium 
prausnitzii spp. and Lachnospiraceae family members 
and a significant increase in Bifidobacterium genus; the 
authors found also differences in the humoral responses 
mainly altered levels of the specific IgA antibodies react-
ing against the aforementioned bacteria. This suggests 
that the imbalance observed in the bacterial commu-
nity may contribute to disease onset [38]. Another place 
heavily exposed to microorganisms, where uncontrolled 
inflammation may lead to autoimmunity, is the skin. 
Recent studies, using different sampling techniques, 
such as skin swabs or punch biopsies, have both found 
a significant reduction in Actinobacteria and Propioni-
bacteria in skin lesions of patients with psoriasis and an 
increase in Firmicutes as compared to healthy dermis [39, 
40]. PsA can be associated with both psoriasis and IBD, 
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suggesting an etiologic overlap between the joint inflam-
mation and both gut and skin pathology in which the 
microbiome may be the common mediator. The group 
of Scher [41] showed very recently a reduced diversity in 
the gut microbiota composition of patients with PsA and 
skin psoriasis when compared to healthy controls. More 
specifically, this study reports a significant reduction in 
members of the bacterial genus Akkermansia, Rumino-
coccus, and Pseudobutyrivibrio in feacal samples from 
PsA patients.
Microbiota and rheumatoid arthritis
RA is an inflammatory autoimmune disease poten-
tially leading to functional disability, with about 30  % 
of patients unable to work after 3  years of disease. It is 
characterized by the positivity of specific autoantibod-
ies [rheumatoid factor (RF) and anti-citrullinated pro-
tein antibodies (ACPAs)] and the presence of an erosive 
simmetric synovitis affecting predominantly small joints 
such as hands, wrists and feet. There is strong evidence 
that the highest joint inflammation level may be observed 
early (75  % erosions within the first 2  years) and that 
timely treatment is able to slow down the progression of 
bone and join damage measured by radiographic scan-
ning. This awareness of the need of early intervention, 
joined to the availability of more effective methods for 
early diagnosis/prognosis and the development of new 
therapeutic tools, pushed clinicians to introduce and 
characterize the concept of “early rheumatoid arthritis” 
(eRA). A comparative study conducted on fecal samples 
of patients with newly diagnosed RA and of patients 
with fibromyalgia showed that the first group had sig-
nificantly lower abundance of common commensals 
including Bifidobacteria and Bacteroides [42]. Another 
study investigated the composition of fecal Lactobacillus 
communities in eRA patients and found a higher diver-
sity of bacteria than in healthy controls [43]. On the other 
hand Chen et al. have recently reported a decreased gut 
microbial diversity in RA patients, which correlated with 
disease duration and autoantibody levels. In fact, analy-
sis of the 16S ribosomal DNA of fecal samples from RA 
patients showed the expansion of rare taxa that allowed 
authors to develop a prediction model identifying three 
genera, Collinsella, Eggerthella, and Faecalibacterium 
segregated with RA disease [44].
Scher et  al. performed 16S sequencing on 114 stool 
samples from eRA patients and controls, and shotgun 
sequencing on a subset of all the samples. Results showed 
an abundance of Prevotella copri spp. with concomitant 
loss of various Bacteroidetes phylum members in the 
stool of RA patients [45]. The inoculation of fecal sam-
ples from eRA patients into germ-free arthritis-prone 
SKG mice showed increased sensitivity to arthritis via 
activation of autoreactive T cells in the intestine. T cell 
activation in these mice was most probably caused by 
dysbiosis. In fact, deep sequencing of the 16S rRNA of 
fecal eRA samples showed a microbiota markedly domi-
nated by Prevotellaceae [46].
Beyond gut microbiome, an accumulating body of evi-
dence strongly evokes a pathogenic role for the altered 
oral microbiota in RA development and disease course. 
Interestingly Zhang et  al. using metagenomic shotgun 
sequencing and a metagenome-wide association study 
(MGWAS) found a concordant dysbiosis of both fecal 
and oral samples from RA patients that was partially 
resolved after RA treatment. In fact, microbiome changes 
correlated with clinical measures in particular, Haemo-
philus spp. was depleted and negatively correlated with 
levels of serum autoantibodies, whereas Lactobacillus 
salivarius was over-represented. This was reinforced by 
the observation that Lactobacillus salivarius was also 
present in increased amounts in very active RA disease 
[15].
The oral healthy microbiome is second only to the gut 
in total microbial species and is extensively represented 
by the bacteria phyla Firmicutes, Bacteroidetes, Proteo-
bacteria, Actoniobacteria, Spirochaetes and Fusobacte-
ria [47]. The periodontitis (PD)-associated bacteria are 
widely studied and Porphyromonas gingivalis, Tannerella 
forsythia, and Treponema denticola are the species most 
frequently associated with this chronic inflammatory 
oral disease [48, 49]. RA and the most severe forms of 
PD share several immunological and morphological 
features, such as increased levels of pro-inflammatory 
cytokines and metalloproteinases that can lead to several 
tissue and bone alterations [43, 50]. Different groups have 
joined efforts in studying the epidemiological association 
between these two diseases aiming at identifying a pos-
sible pathogenic link. The most convincing hypothesis is 
that certain species of bacteria present in the oral cavity 
induce break of tolerance, by exerting an abnormal cit-
rullination activity. Citrullination is a post-translational 
reaction consisting of the conversion of arginine into 
citrulline, which can have important consequences for 
the protein structure and function. Citrullinated pro-
teins arise by the activity of peptidyl-arginine-deimi-
nases (PAD) enzymes that catalyze the modifications of 
peptidyl-arginine to peptidyl-citrulline on different self-
proteins, among which α-enolase, keratin, fibrinogen, 
fibronectin, collagen, and vimentin; loss of tolerance to 
such neo-epitopes elicits an ACPAs response that may 
result into disease [51]. In 2004 Rosenstein et  al. sug-
gested that the humoral response to P. gingivalis could 
provide a trigger for the development of RA [52]. Porphy-
romonas gingivalis is actually the only known bacterium 
carrying a PAD enzyme [53]. Although PAD enzymes 
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expressed in P. gingivalis are quite different from the 
human variants it has been reported that these bacterial 
enzymes can lead to irreversible citrullinated peptides, 
mainly in α-enolase and fibrinogen, in RA patients [54, 
55]. The importance of oral bacteria as a disease-causing 
element by this mechanism has been corroborated by a 
number of studies showing strong correlations between 
increased prevalence of periodontitis and severity in 
RA, as well as, by the detection of anaerobes and high 
antibody titers against periodontal bacteria both in 
the serum and in the synovial fluid of RA patients [45, 
56, 57]. A recent paper from Scher et al. by using a 16S 
rRNA pyrosequencing approach, showed that severe PD 
is already present at the onset of RA in newly diagnosed 
and untreated patients. Although Scher demonstrated 
that RA patients have twice the amount of P. gingivalis 
as compared to healthy controls this observation did not 
correlate with the presence of APCA [58]. Lange et  al. 
have recently demonstrated that children with CCP-pos-
itive Juvenile Idiopathic Arthritis (JIA) have higher anti-
body responses to P. gingivalis and poor oral health than 
children with APCA-negative JIA [59].
In a murine model of chronic Ag-induced arthri-
tis (AIA) Queiroz-Junior et  al. showed that PD resulted 
simultaneously in synovial joint hyperplasia, severe alve-
olar bone loss, migration of osteoclasts and release of 
pro-inflammatory cytokines; moreover anti–TNF-α ther-
apy was able to prevent the development of both AIA and 
PD [60]. Two other groups evaluated the role of the con-
ventional therapy for PD and root planning in improving 
RA inflammation and activity suggesting a link between 
PD and RA. In the first study the authors showed a bet-
ter outcome in RA patients who received a PD treatment 
in addition to standard disease modifying antirheumatic 
drugs (DMARDs) and anti-TNF-α [61]. The second study 
reported the presence of PD in RA patients as a prognos-
tic factor associated to a poor response to anti-TNF-α 
therapy [62].
Finally, the first case of a complete and long-lasting 
recovery after periodontal treatment, in a male patient 
with newly onset of RA and PD has been recently 
reported, suggesting that in selected early RA cases, 
prompt periodontal infection treatment may induce 
disease regression, thus avoiding the development of a 
chronic and progressive arthritis [63].
Environmental factors influencing arthritis and microbiota
Smoke
Environmental factors that influence periodontal bacte-
rial community may represent risk factors for the devel-
opment of autoimmune diseases. One of the most well 
studied risk factors affecting both periodontal disease 
and arthritis is smoke [64, 65]. Cigarette smoke can lead 
to several immune dysregulations, such as modulation 
of apoptosis with the increased exposure of sequestered 
intracellular autoantigens and increased release of free 
radicals that can cause mutations or gene activation 
[66, 67]. It can also induce alterations of T cell func-
tion, impair humoral responses and change the balance 
between regulatory and inflammatory cytokines [66, 68–
70]. Onozaki et al. incubated human synovial fibroblasts 
with 5 % cigarette smoke extract and by using microarray 
and real time PCR observed a significant upregulation of 
the heat shock proteins DnaJA4, DnaJB4, DnaJC6, HspB8 
and Hsp70 that have been shown to lead the activation 
of inflammatory signaling pathways in RA [71]. In RA 
patients, cigarette smoke can act via the induced produc-
tion of ACPAs. The smoke attributable risk for RA is vari-
able; a large prospective study reports a risk ratio ranging 
from 2.6 to 3.8 in former and heavy smokers compared 
with non smokers [72]. The association is stronger in 
men, in patients positive for ACPAs and expressing the 
shared HLA epitope (HLA-DRB1) [73, 74]. Data on 
tobacco consumption and RA disease severity are con-
trasting, however there is agreement on the increase in 
extra-articular manifestations and earlier onset of dis-
ease in RA smokers as compared to non-smokers [75]. 
Of note, different authors and registries data highlighted 
a significant lower response to synthetic and biological 
(anti-TNF-α) drugs, as well as, a reduction in the prob-
ability of reaching disease remission in RA smokers [76–
78]. The negative impact of tobacco on drug response can 
be also related to its effect on the drug metabolic rate and 
consequent pharmacokinetics alteration as previously 
reported [79]. In PD, the effect of smoke on microbiota 
are controversial, however, it has been demonstrated that 
P. gingivalis, Tannerella forsythia, Aggregatibacter actino-
mycetemcomitans spp. and, more recently, Parvimonas 
and Treponema have a higher prevalence on the oral 
cavity of smokers than in non-smokers subjects [80, 81]. 
Few are the studies that have analysed the influence of 
smoking on the composition of the gut microbiota. How-
ever Biedermann et  al. have recently showed significant 
changes after smoking cessation with an increase in Fir-
micutes and Actinobacteria accompanied by a reduction 
of Bacteroidetes [82].
Diet
Diet is another modifiable environmental factor that 
can influence both microbiota composition/diversity 
and arthritis onset/outcome. A certain cause-effect rela-
tion between diet and arthritis is hard to perform thus 
genetics and living conditions cannot be ruled out as 
important interfering factors. However the relevance of 
diet composition is also suggested by the significant dif-
ferences in the human microbiota structure between 
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geographically distant populations [83, 84]. It has been 
reported that a diet rich in animal proteins, simple sugars 
and saturated fats, all typical components of food intake 
in western countries, is characterized by a less diverse 
microbiome associated with the Bacteroidetes entero-
type, whereas Prevotella is the most prevalent in people 
assuming high fiber diets rich in fruits and vegetables 
[85]. The fecal microbiota of African children (charac-
terized by a diet prominently composed of plant-derived 
carbohydrates) is enriched in Prevotella and Xylanibacter 
and depleted in Bacteroides compared to the European 
and USA children [86]. Recent data also demonstrated 
that dietary intervention can modify, even rapidly, gut 
microbiota structure and overwhelms inter-individual 
differences in microbial gene expression. Subjects replac-
ing a diet high in fibers with a short term one (ad libi-
tum for 5 days) rich in animal-based high fat and proteins 
have an increase in bile-tolerant microorganisms (Alis-
tipes, Bilophila, and Bacteroides phyla) and a decrease 
in Firmicutes, such as Roseburia, Eubacterium rectale 
and Ruminococcus bromii that metabolize dietary plant 
polysaccharides [87]. However, recently, Cotillard et  al. 
demonstrated that dietary intervention, such as a change 
to a low caloric diet, is able to increase microbiome gene 
richness only in overweight subjects characterized by low 
gene richness at baseline, suggesting that the responses 
to nutritional modulation are influenced by the initial 
microbiota structure present in a given individual [88]. 
A 2009 Cochrane review evaluated the effects of dietary 
interventions in RA patients which included fourteen 
randomized clinical trials (RCTs) and one case control 
study, with a total of 837 patients [89]. Among these 
RCTs, one found that fasting, followed by 13  months 
on a vegetarian diet, can reduce pain and morning stiff-
ness but was unable to restore the physical function with 
respect to control group [90]. Another RCT found that 
a 12-week Cretan Mediterranean diet could reduce pain 
but was unable to rescue physical function or morning 
stiffness [91]. Finally, two other RCTs compared 4 weeks 
elemental diet with an ordinary diet and reported no sig-
nificant differences in pain, function or stiffness [92, 93]. 
Based on these observations the authors of the Cochrane 
concluded that favorable disease outcomes given by any 
dietary manipulation, including vegetarian, mediterra-
nean, elemental and elimination diets, on RA patients 
are not conclusive. The uncertainty related to the validity 
of such results is due to the poor quality of the reported 
data and also to the possible adverse events related to 
severe diet restriction. As alternative to full diet change, 
diet supplementation with derivatives of polyunsaturated 
fatty acid (PUFA) omega-6 has also been investigated. 
Arachidonic acid (ARA), a product of PUFA-omega-6, 
is a substrate for the synthesis of important mediators of 
inflammation called eicosanoids which are known to par-
ticipate in the pathogenesis of chronic joints synovitis in 
RA and SpA and are commonly target by NSAIDs [94]. 
Other PUFAs with similar beneficial characteristics are 
the omega-3 eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA) that are present in seafood, especially 
oily fish, and in fish oil-type supplements [95]. These 
fatty acids are involved in ARA availability/metabolism 
and influence several immuno-inflammatory responses 
such as dendritic and T cell function, the production of 
inflammatory cytokines and reactive oxygen species in 
the health and in RA patients [96–100]. In western coun-
try diet generally contains much more omega-6 than to 
omega-3 PUFA probably due to excessive intake of pro-
cessed vegetable oils. In mouse models of arthritis a diet 
rich in fish omega-3 oils was able to delay disease onset 
and reduce joint synovitis compared to an omega-6 based 
diet [101, 102]. Several authors evaluated the effect of 
such a dietary composition in patients with RA with con-
trasting results, however a recent meta analysis includ-
ing selected published studies between 1985 and 2009 
has reported a moderate role for supplementation with 
omega-3 fatty acids in decreasing joint pain and morn-
ing stiffness [95]. Vitamin D is another dietary nutrient 
that has demonstrated increasing relevance in reduc-
ing inflammatory autoimmune diseases in the last years. 
Vitamin D levels are influenced by several factors such 
as sun exposure, age, ethnicity, body mass index, use of 
medications and supplements. It is known that vitamin D 
can reduce inflammation and modulate the immune sys-
tem and an association between vitamin D serum levels 
and rheumatoid disease in mouse models of arthritis has 
been reported [103, 104]. Furthermore, the prevalence of 
RA is higher in areas where vitamin D deficiency is pre-
sent, however data regarding vitamin D supplementation 
in RA patients are insufficient and contrasting [105, 106].
Stress
Stress consists in a stimulus that precipitates a reaction 
in the brain with the consequent activation of physi-
ological fight-or-flight responses [107, 108]. This reac-
tion can modify hypothalamic–pituitary-adrenal (HPA) 
axis by the secretion of hormones like gluco-corticoid, 
mineral-corticoid, epinephrine and norepinephrine that 
are able to modulate the immune system by interfering 
with cytokine secretion and immune cell redistribution. 
The impact of stress on immune function has been exten-
sively investigated in healthy subjects exposed to differ-
ent type of stress factors (eustress vs distress), intensity 
(minor stress such as work stress and interpersonal rela-
tions, or major stress like death or severe illness of a par-
ent) and duration (acute vs chronic stress) [109–111]. 
Stress can modulate the immune system by inducing a 
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shift away from cellular immunity (T helper type 1, Th1) 
towards humoral responses (T helper type 2, Th2) [112, 
113]. The effect of stress can be different according to the 
type of stressor, subject and environment, however it is 
generally accepted that short-term stress can enhance 
innate and adaptive immune responses, whereas chronic 
or long-term stress can induce immunosuppression by 
decreasing immune cell numbers and function and/or 
increasing active immunosuppressive mechanisms [114, 
115]. Since stress has the ability of modulating immune 
function and the empirical observations that stress could 
precede autoimmune onset and disease flares, different 
authors evaluated the impact of stress in these patholo-
gies [116–118]. A proposed mechanism for the brain-
immune axis to influence disease activity is the induction 
of pro-inflammatory cytokine secretion; indeed an 
increase in IL-6 and IL-1 has been observed during 
acute stress in patients with autoimmune disorders [112, 
119–121]. Stress can also be an autoimmune inducer by 
influencing lymphocyte number and activity. It has been 
reported, in fact, that an acute stress in healthy subjects 
is able to induce an imbalance between peripheral effec-
tor T cells (CD8posCCR7neg) and Tregs (CD4posFOXP3pos) 
in favor of the effector arm of the immune system [114]. 
Despite these observations, strong evidences for a clini-
cal role of stress in RA onset/flares are still a matter of 
controversy. Different authors in fact found no significant 
association between exposure to previous stressful events 
and increased incidence of RA [122, 123], furthermore, 
in most of the studies no significant correlation between 
disease severity and major stressors has been found [119, 
124]. In contrast to the studies mentioned above, more 
recently, Zautra et  al. have reported an increased inci-
dence of disease flare up in RA women exposed to minor 
stress [125] and Potter’s group described a worse dis-
ease presentation and radiographic outcome in a 5-year 
follow-up study of RA patients exposed to high levels 
of daily minor stress [126]. The axis between brain and 
immune system involves also the gut microbiome. The 
complex network between gut microbiota and the brain 
encompasses the central and autonomic nervous system 
and communicates via hormonal neural cytokine path-
ways. In recent years there is a growing interest in eluci-
dating this network and in finding correlations between 
microbiota composition/diversity and stress related 
disturbances such as depression anxiety and pain. The 
first evidence comes from several experiments on stress 
induction in GF mouse models that reported a reduction 
of the anxiety-like behaviors in GF mice as compared 
to specific pathogen free mice; furthermore this behav-
ioral condition was confirmed by changes in plasticity-
related genes in the hippocampus and amygdala [127]. 
Always in mice, Nishino et  al. showed that the type of 
commensal microbiota present in the gut can influence 
behavior by describing that the monoassociation with 
Blautia coccoides spp. in GF mice reduced anxiety-like 
behavior in open field, whereas monoassociation with 
Bifidobacterium infantis reduced activity without affect-
ing anxiety [128]. Another group using a mouse model 
of induced anxiety and depression via olfactory bulbec-
tomy, reported alterations in gut microbiota, which were 
related to the activation of the hypothalamic pituitary 
adrenal axis [129]. Finally last year Topol et  al. showed 
in rats a reduction in the total number of Xbp1pos lym-
phocytes in the gut associated lymphoid tissue of the 
ileum in animals under induced chronic social stress sug-
gesting a role for Xbp1 expression levels as a trigger of 
inflammation and thus as potential link between stress 
and autoimmunity [130]. For what concerns depression 
and its interplay with gut flora few relevant data is avail-
able. Only, recently Naseribafrouei addressed this topic 
and demonstrated an overrepresentation of Bacteroi-
detes spp. and a reduction of Lachnospiraceae in the fecal 
microbiota of 37 patients with depression [131]. In indi-
viduals suffering of irritable bowel syndrome, in which 
anxious/depressed status plays an important role, it was 
described a reduction in Bacteroidetes and an increase in 
Firmicutes phylum representation [132–134]. Behavior 
modifications, induced by the probiotic mix, were reflect-
ing the reduction in microglial activation and cerebral 
monocyte infiltration as well as the decrease in circulat-
ing TNF-α levels [135]. Despite these efforts studies that 
put together microbiota, nervous system and chronic 
inflammatory diseases in clear correlation of cause effect 
are still lacking.
Therapy, microbiota and arthritis
Probiotics are defined as living organisms that if ingested 
in adequate amount can confer a health benefit to the 
host [136, 137]; lactic acid and bifidobacteria are the 
most frequently used types of bacteria. Probiotic use 
has been recently analysed in animal models of arthritis 
whereas few studies have been conducted in humans. 
First evidence for beneficial effects comes from two 
papers by So et al. in which they studied the outcome of 
L. casei (5 ×  109 CFU ×  3 times per week) administra-
tion in CIA rats [138, 139]. Probiotic oral assumption 
produced a reduction in inflammatory (i.e. IL-1α, IL-6, 
IL-12, IL-1 and TNF-α) and an increase in regulatory 
cytokines (IL-10) accompanied by an improvement in 
disease signs, such as paw swelling and cartilage tissue 
damage. These results were confirmed by a more recent 
study, in which assumption of L. casei (2 × 108 CFU/mL 
daily) demonstrated to exert significant protection in a 
CIA rat model by preventing synovial infiltration, pannus 
formation, and bone destruction compared to control 
Page 8 of 12Diamanti et al. J Transl Med  (2016) 14:233 
rats and CIA rats treated with indomethacin [140]. In RA 
patients, three RCTs have been recently published with 
contrasting results. The first study evaluated the effects 
of the oral administration of a probiotic containing Bacil-
lus coagulans (2 billion CFU) plus green tea extract, 
methy-sulfonyl-methane, vitamins and minerals versus 
placebo on 45 RA patients during a 2 months follow-up 
[141]. Patients receiving probiotic treatment resulted in a 
greater improvement in their global and self assessed dis-
ability as well as a greater reduction in serum C reactive 
protein (CRP) tender and swollen joints count. In 2011 
Pineda et al. examined the effect of probiotic supplemen-
tation in 15 patients with established moderate RA under 
DMARDs, 14 matched RA patients were used as controls 
[142]. Patients received capsule containing either 2-bil-
lion CFU Lactobacillus rhamnosus and Lactobacillus 
reuleri or capsule without bacteria for a follow-up period 
of 3 months. At the end of the study there was no signifi-
cant difference between treated and non-treated individ-
uals in terms of clinical disease activity scores or in the 
main inflammatory serological parameters and cytokines. 
The last trial conducted by an Iranian group tested the 
effect of L. casei on 22 women with established RA as 
adjunctive therapy to the ongoing stable synthetic immu-
nosuppressant in comparison to 24 women with RA that 
were used as control group [143]. Authors described a 
reduction in the swollen and tender joints count, as well 
as, in the patient global health and CRP at 3 months only 
in the group receiving L. casei (capsule containing a mini-
mum of 108 CFU). Moreover, more patients in the probi-
otic group were found to have moderate response to the 
treatment and a reduction of serum levels of inflamma-
tory cytokines compared to the placebo group. However, 
looking in depth, the beneficial effects given by probiot-
ics appear less solid; in fact one should take into account 
that patients at baseline had a mean number of swollen 
and tender joints of zero and a normal CRP reflected by 
a mean disease activity score on 28 joints (DAS28) of 
2.6 that is a value in which patients are already consid-
ered at clinical remission. Interestingly in 2009 one pilot 
study reported a significant reduction of bath ankylosing 
disease activity index (BASDAI) in patients with active 
SpA associated to quiescent ulcerative colitis (UC) after 
treatment with a probiotic regimen of Lactobacillus aci-
dophilus and Lactobacillus salivarius [144]. However 
more recently a RCT developed by Jenks et al. involving 
63 patients with active SpA receiving either a probiotic 
containing at least 108 CFU of Streptococcus salivarius, 
Bifidobacterium and Lactobacillus acidofilus or placebo 
over a period of 3  months, failed to demonstrate sig-
nificant differences in any of the clinical disease activity 
or functional domain such as BASDAI, bath ankylos-
ing functional index (BASFI) and Maastricht spondylitis 
enthesitis score (MASES) between the 2 groups [145]. 
Of note, Bernston et al. have recently reported a case of 
a patient with severe JIA that a significantly improved his 
clinical status after several months of therapy with solely 
enteral nutrition. Patient also showed changes in his gut 
microbiome and metabolome [146].
There is a growing awareness that different drugs such 
as antibiotic and immunosuppressant can both influence 
and to be influenced by microbiota diversity and compo-
sition. Although the impact of antibiotics on microbiome 
is mostly temporary, their frequent use or administra-
tion during early infancy can exert permanent effects 
only partially understood. It is known that anti-cancer 
therapy frequently used also in treating chronic inflam-
matory arthritis, such as methotrexate and cyclophos-
phamide, changes dramatically the gut microflora. After 
these treatments often occurs a general depletion of the 
gut microbiota, the drop in bacteria diversity is accompa-
nied by a reduction in the commensal anaerobic species 
in favor of potential pathogens that can lead to a deteri-
oration of the gut barrier, altering epithelial cell perme-
ability with consequently bacterial translocation [147]. 
The hypothesis that the gut microbiota can interfere with 
the outcome of anticancer therapy is not new, but only 
recently two independent groups have addressed this 
issue using mouse models. Iida et  al. [148] showed that 
CpG-oligonucleotide administration in antibiotic-treated 
or in GF mice resulted in an impaired cytokine produc-
tion by tumor-infiltrating myeloid-derived cells; further-
more these mice presented a deficient production of 
reactive oxygen species and cytotoxicity after chemother-
apy. The other group [149] demonstrated that antibiotic-
treated mice or GF were resistant to cyclophosphamide 
depleting action probably because of a reduction in 
the generation of Th17 cells, suggesting that an intact 
microbiota is necessary for successful tumor control in 
response to therapy. Sulphasalazine (SSA) is a drug com-
monly used both in IBD and chronic inflammatory arthri-
tis such as SpA and RA. Different authors have analysed 
the role of the intestinal microbiota in SSA metabolism 
and found a reduction of SSA anti-inflammatory func-
tion in patients with UC previously treated with severe 
antibiotic regimens [150, 151]. In contrast to these obser-
vations, Lee et al. [152] did not find significant changes in 
plasma and urinary levels of SSA and of its metabolites in 
a small group of RA patients in whom a multi-strain pro-
biotic regimen was administered. The impact of micro-
biota on the therapy outcome using biologics has not 
been extensively explored. A pioneer study addressing 
this issue focused at the analysis of fecal samples isolated 
from 33 Crohn Disease (CD) patients treated with anti-
TNF-α aiming to identify, based on the gut microbiota 
composition, a factor predictive of relapse. They found a 
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lower rate of bacterial species belonging to the Firmicutes 
phylum in relapse as compared to non relapse patients, 
and a consistent drop in F. Prausnitzii spp. that was able 
to predict the incidence of disease flares [153].
Conclusions
In the last years there is a growing awareness regarding 
the role of the microbiota in the onset and outcome of 
patients with SpA and RA. Recently a reduction in the 
gut microflora diversity and alterations in its composi-
tion, similar to that observed in IBD, have been reported 
in patients with PsA; the increased permeability of the 
intestinal epithelial cell layer as well as the increased 
exposure to microbial products has been proposed as a 
mechanism that can connect dysbiosis to joint inflam-
mation. In RA patients the most supported association 
between disease and microbiota is with the oral dysbiosis 
usually observed in patients with periodontitis. In par-
ticular, the presence of P. gingivalis could provide a trig-
ger for RA onset in susceptible individuals by leading to 
the irreversible generation of citrullinated peptides.
To better understand the gut-joint link it is important 
to consider that several environmental factors such as 
diet, smoking and stress can influence both the micro-
biota diversity/composition and the arthritis onset/
outcome. The relevance of diet is suggested by the differ-
ences in the gut microbiota between geographically and 
life style distant populations. In general, people assum-
ing a diet rich in animal proteins, simple sugars and fats 
have a reduced diversity of gut microbiota with a preva-
lence of Bacteroidetes spp. Dietary intervention, fish oil, 
reduction in animal protein intake among others, can 
modify bacterial diversity in the gut sometimes leading 
to a mild reduction of joint inflammation. Smoking can 
cause several immune dysregulation and represents a risk 
factor for arthritis onset; in addition smoking can also 
affect arthritis outcome, by interfering with therapeu-
tic response to synthetic and biological drugs. Smoking 
influences both oral and gut microflora with an increase 
in P. gingivalis, Tannerella and Bacteroidetes that can be 
partially reverted after smoking cessation. It is known 
that stress can influence the immune function and con-
sequently autoimmune diseases via different serologi-
cal and cellular pathways; a clinical role for stress in the 
onset and flares of patients with chronic arthritis has 
been reported, however it needs to be better elucidated. 
The axis between brain and immune system involves also 
the microbiota as supported by studies using several ani-
mal models and by the recent description of gut micro-
biota alterations in patients with depression and irritable 
bowel syndrome.
To identify individual parameters able to predict dis-
ease severity and therapeutic outcome in RA and SpA 
patients is still an unmet priority for the rheumatologist. 
A better elucidation of the potential role of the individual 
microbiota in these diseases could be a promising tool 
that deserves to be explored. Further studies are needed 
to better clarify how the changes in gut composition/
diversity induced by environmental factors can reflect 
in the autoimmune arthritis development and prognosis 
however current knowledge strongly suggests to include 
smoking cessation and dietary intervention in the man-
agement of autoimmune arthritis patients.
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